Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.

医学 血沉 安慰剂 痹症科 类风湿性关节炎 随机对照试验 人口 关节炎 临床试验 内科学 外科 胃肠病学 病理 环境卫生 替代医学
作者
Huijing Huang,Jialin Teng,Chunde Bao,Xinghai Han,Lingyun Sun,Jiang-hua Xu,Xing-Fu Li,Huaxiang Wu
出处
期刊:PubMed 卷期号:121 (7): 615-9 被引量:31
标识
DOI:10.1097/00029330-200804010-00008
摘要

A novel anti-rheumatic drug, T-614, has been shown to have an anti-inflammatory effect and to improve abnormal immunological findings in rheumatoid arthritis (RA). To assess the safety and efficacy of T-614 versus placebo in patients with active RA we conducted a 24-week clinical study in 280 Chinese patients.In a multicenter, randomized, double blind, placebo controlled study, 280 patients were randomly assigned to receive placebo (n = 95) or T-614 at 50 mg (n = 93) or 25 mg (n = 92) daily. Active disease was defined by 4 of the following 5 criteria: >or= 5 tender joints, >or= 3 swollen joints, morning stiffness lasting for >or= 60 minutes, and Westergren erythrocyte sedimentation rate (ESR) >or= 28 mm/h, the assessment of pain at the rest by patient as moderate or severe. Clinical and laboratory parameters were analyzed at baseline, 2, 4, 6, 12, 18 and 24 weeks. The primary efficacy variable at week 24 was the American College of Rheumatology (ACR) response rate using the intent-to-treat population.The ACR response rate was significantly higher in the T-614 treatment group compared with the placebo group within 8 weeks after the initiation of treatment. After 24 weeks, the 25 mg/d and 50 mg/d dosage groups and the placebo group showed 39.13%, 61.29% and 24.21% in ACR20 and 23.91%, 31.18% and 7.37% in ACR50, respectively. A time-response in ACR response was observed, with clear superiority for the 25 mg/d and 50 mg/d dosage groups compared to placebo (P < 0.0001), and the 50 mg/d dose compared to the 25 mg/d dose (P < 0.05) when using the ACR response analyses after 24 weeks. ESR and c-reactive protein (CRP) were significantly different in the treatment groups after 24 weeks. The incidence of adverse events (AEs) was not significantly higher with T-614 than with placebo, but upper abdominal discomfort, leucopenia, elevated serum alanine aminotransferase (sALT), skin rash and/or pruritus were more common in the 50 mg and 25 mg dosage groups.T-614, a new slow-acting drug, is effective in treatment of rheumatoid arthritis and is well tolerated.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
YY完成签到,获得积分10
刚刚
刚刚
小北完成签到,获得积分10
刚刚
淼漫完成签到,获得积分10
刚刚
1秒前
悦耳的盼夏完成签到,获得积分10
1秒前
1秒前
2秒前
2秒前
2秒前
Ming完成签到,获得积分10
2秒前
某杏完成签到,获得积分10
2秒前
柯一一应助落寞的紫山采纳,获得10
2秒前
2秒前
2秒前
3秒前
李爱国应助星魂残月夜采纳,获得10
3秒前
南柯完成签到,获得积分10
4秒前
5秒前
guons发布了新的文献求助10
5秒前
CodeCraft应助dayday采纳,获得10
5秒前
zxy发布了新的文献求助10
5秒前
小苏打完成签到,获得积分10
6秒前
o30发布了新的文献求助10
6秒前
6秒前
听南完成签到,获得积分20
6秒前
充电宝应助WANGSONGLU采纳,获得10
6秒前
7秒前
Jimmybythebay完成签到,获得积分10
7秒前
qqq完成签到,获得积分10
7秒前
7秒前
fanyouxin完成签到,获得积分10
7秒前
赘婿应助tylerconan采纳,获得30
7秒前
HP发布了新的文献求助10
7秒前
forward5完成签到,获得积分10
7秒前
学了个习完成签到,获得积分20
8秒前
8秒前
哇咔咔完成签到,获得积分10
9秒前
9秒前
9秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969398
求助须知:如何正确求助?哪些是违规求助? 3514239
关于积分的说明 11173064
捐赠科研通 3249531
什么是DOI,文献DOI怎么找? 1794934
邀请新用户注册赠送积分活动 875501
科研通“疑难数据库(出版商)”最低求助积分说明 804827